CellSource Past Earnings Performance
Past criteria checks 2/6
CellSource has been growing earnings at an average annual rate of 35.2%, while the Life Sciences industry saw earnings growing at 28.2% annually. Revenues have been growing at an average rate of 26.7% per year. CellSource's return on equity is 14.3%, and it has net margins of 18.4%.
Key information
35.2%
Earnings growth rate
-29.0%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 26.7% |
| Return on equity | 14.3% |
| Net Margin | 18.4% |
| Next Earnings Update | 13 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CellSource makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 4,624 | 850 | 1,995 | 72 |
| 31 Oct 23 | 4,510 | 923 | 1,866 | 72 |
| 31 Jul 23 | 4,807 | 1,103 | 1,683 | 87 |
| 30 Apr 23 | 4,746 | 1,119 | 1,571 | 87 |
| 31 Jan 23 | 4,512 | 1,078 | 1,485 | 87 |
| 31 Oct 22 | 4,273 | 1,017 | 1,393 | 87 |
| 31 Jul 22 | 3,690 | 812 | 1,277 | 71 |
| 30 Apr 22 | 3,276 | 691 | 1,166 | 71 |
| 31 Jan 22 | 3,120 | 693 | 1,065 | 71 |
| 31 Oct 21 | 2,922 | 651 | 998 | 71 |
| 31 Jul 21 | 2,648 | 544 | 1,020 | 10 |
| 30 Apr 21 | 2,312 | 424 | 952 | 10 |
| 31 Jan 21 | 2,033 | 310 | 902 | 10 |
| 31 Oct 20 | 1,855 | 274 | 825 | 10 |
| 31 Jul 20 | 1,750 | 212 | 822 | 7 |
| 31 Oct 19 | 1,611 | 199 | 813 | 7 |
| 31 Oct 18 | 1,212 | 193 | 572 | 6 |
| 31 Oct 17 | 519 | 111 | 136 | 4 |
Quality Earnings: 4880 has high quality earnings.
Growing Profit Margin: 4880's current net profit margins (18.4%) are lower than last year (23.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4880's earnings have grown significantly by 35.2% per year over the past 5 years.
Accelerating Growth: 4880's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4880 had negative earnings growth (-21.2%) over the past year, making it difficult to compare to the Life Sciences industry average (-19.3%).
Return on Equity
High ROE: 4880's Return on Equity (14.3%) is considered low.